PyramIDH
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 48 patients (estimated)
- Sponsors
- Institut de Recherches Internationales Servier
- Collaborators
- Servier Bio-Innovation LLC
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2062
- NCT Identifier
- NCT06465953
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.